decisionhealth Newsletters, Coder Pink Sheets - 2015 Issue 9 (September)
Drug billing: Verify J codes and units of service, prepare for more MUEs after OIG report
Subscribe or sign in to view the full article.
Article Overview
This article discusses a Medicare Part B drug-billing report from the HHS Office of Inspector General and the operational implications for practices billing injectable drugs. It covers reported payment errors, the role of HCPCS J codes and units of service, expected Medicare edit changes, documentation and charge-master considerations, and references to NDC-based claim validation resources. The piece is aimed at coders, billing staff, and oncology or infusion practices that submit drug claims and want to reduce preventable billing errors.
Why This Topic Matters
Drug claims are a frequent source of payment errors, and the article explains why practices may face stricter Medicare edits, audits, and recoupments. Understanding the article helps billing teams review charge capture, coding consistency, and claim-scrubber logic for injectable Part B drugs.
Article Sections
-
OIG report and Medicare drug overpayments
Summarizes the reported audit findings and the broader context for injectable Part B drug payment issues. Discusses why the report has prompted concern about claims accuracy and post-payment review.
-
Dosage capture and unit reporting on charge documents
Explains the importance of aligning documentation, charge documents, and drug administration records. Covers general considerations for supporting correct units of service on claims.
-
HCPCS J code changes and examples of dosage-driven reporting
Reviews the article’s discussion of changing drug codes and the move toward dosage-based reporting. Includes examples used in the article to illustrate why code selection and unit calculation are operationally important.
-
Claim scrubber edits and diagnosis-based validation
Describes how practices may configure claim-editing tools to flag potentially inconsistent drug claims. Addresses general workflow considerations for validating drug codes against diagnosis information.
-
NDC reporting and crosswalk resources
Covers the article’s discussion of NDC reporting requirements and reference tools used to confirm drug coding. Notes the role of external resources in reducing coding and billing errors.
What You Will Learn
- How the OIG report relates to Medicare Part B injectable drug billing
- Why units of service and documentation accuracy are important for drug claims
- How changing HCPCS drug codes can affect billing workflows
- How claim scrubbers and crosswalk tools may be used to support claim validation
- What general types of controls may help reduce drug-billing errors
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle teams
- Oncology practices
- Infusion centers
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com